Clinical trial data have shown that immune-checkpoint inhibitors, such as those against programmed cell death 1 (PD-1), can be effective in patients with recurrent or metastatic NPC (20, 21). This evidence concerns the gene PDCD1 and nasopharyngeal carcinoma.